Abstract
AbstractNodal marginal zone B-cell lymphoma (NMZL) is a rare subtype of non-Hodgkin lymphoma, usually presented at advanced stage. The treatment for NMZL is currently consistent with follicular lymphoma which includes observation for asymptomatic patients to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or CHOP plus rituximab regimen, fludarabine or bendamustine and rituximab (B-R) for advanced, symptomatic patients. The B-R regimen is effective and could be evaluated further as the first-line therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
